BindingDB logo
myBDB logout

48 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27419473 4 Neolignans from the Arils of Myristica fragrans as Potent Antagonists of CC Chemokine Receptor 3.EBI Kindai University
25497216 99 Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
23142617 57 Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.EBI AstraZeneca
23116889 88 Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: optimising in vivo clearance.EBI AstraZeneca
23075267 85 Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.EBI Bristol-Myers Squibb Company
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
23031591 90 The discovery of CCR3/H1 dual antagonists with reduced hERG risk.EBI AstraZeneca
23046963 23 Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.EBI Toray Industries, Inc.
23031649 4 The therapeutic journey of benzimidazoles: a review.EBI Punjabi University
23021991 153 Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.EBI AstraZeneca
22749826 28 Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.EBI Toray Industries, Inc.
18752960 48 Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.EBI Astellas Pharma. Inc.
17951061 20 Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.EBI Astellas Pharma Inc.
18096386 131 From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.EBI Bristol-Myers Squibb Company
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
14505678 21 Design and synthesis of novel CCR3 antagonists.EBI Roche Palo Alto
21940167 12 Design and synthesis of a library of chemokine antagonists.EBI Novartis Institutes of Biomedical Research
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
19620010 43 Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.EBI Astellas Pharma Inc.
19131247 42 Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
19010676 28 Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.EBI Bristol-Myers Squibb Company
18160284 46 From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.EBI Bristol-Myers Squibb Company
17720492 107 Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).EBI Bristol-Myers Squibb Company
17532633 29 Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists.EBI UCB Pharma SA
17418570 141 CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16931001 93 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16698264 37 Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.EBI Merck Research Laboratories
16539392 29 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.EBI Takeda Pharmaceutical Company Limited
15908209 25 The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists.EBI Schering Plough Research Institute
15771462 125 Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI Pharmaceutical Research Institute
15743194 91 Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.EBI Biographics Laboratory 3R
15713390 53 The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.EBI Schering Plough Research Institute
15664858 36 N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.EBI Pharmaceutical Research Institute
15664834 31 Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators.EBI Boehringer Ingelheim Pharma GmbH and Co. KG
15026042 50 Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12166951 146 Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.EBI Bristol-Myers Squibb Company
12067561 96 CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.EBI Bristol-Myers Squibb Company
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11378374 39 Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2.EBI SmithKline Beecham Pharmaceuticals
11378373 33 Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.EBI SmithKline Beecham Pharmaceuticals
11354381 19 Discovery of a novel CCR3 selective antagonist.EBI Banyu Tsukuba Research Institute
11311066 76 Design, synthesis, and discovery of a novel CCR1 antagonist.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11206474 51 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
10821717 29 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.EBI Takeda Chemical Industries, Ltd.